Study identifier:PT003008-00
ClinicalTrials.gov identifier:NCT01970878
EudraCT identifier:N/A
CTIS identifier:N/A
A 28-Week, Multi-Center, Randomized, Double Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® as an Active Control
Chronic obstructive pulmonary disease (COPD)
Phase 3
No
GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
All
892
Interventional
40 Years - 80 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Apr 2019 by Pearl Therapeutics, Inc.
Pearl Therapeutics, Inc.
-
This is a multi-center, randomized, double-blind, parallel group, chronic dosing, active-controlled, 28-week safety extension study of the two pivotal 24-week safety and efficacy studies (Studies PT003006 and PT003007). This study is designed to assess the long-term safety and tolerability of Glycopyrrolate (GP) and Formoterol Fumarate (FF) combination (GFF) metered dose inhaler (MDI), GP MDI, and FF MDI in subjects with moderate to very severe COPD over a total observation period of 52 weeks. Open-label Spiriva is included as an active control. To be eligible for this study, a subject must complete participation in Study PT003006 (NCT01854645) or Study PT003007 (NCT01854658).
Location
Location
Birmingham, AL, United States
Location
Andalusia, AL, United States
Location
Jasper, AL, United States
Location
Glendale, AZ, United States
Location
Tucson, AZ, United States
Location
Anaheim, CA, United States
Location
Carlsbad, CA, United States
Location
Lakewood, CA, United States
Arms | Assigned Interventions |
---|---|
Experimental: GFF MDI (PT003) | Drug: GFF MDI (PT 003) GFF MDI administered as two puffs BID |
Experimental: GP MDI (PT001) | Drug: GP MDI (PT001) GP MDI administered as two puffs BID |
Experimental: FF MDI (PT005) | Drug: FF MDI (PT005) FF MDI administered as two puffs BID |
Active Comparator: Open-label tiotropium bromide inhalation powder Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®) | Drug: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®) Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI) |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.